TARS Insider Trading
Tarsus Pharmaceuticals, Inc. | Biological Products, (No Diagnostic Substances)
Comprehensive Trading Performance Summary
The investment history of corporate insiders at Tarsus Pharmaceuticals, Inc. provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Biological Products, (No Diagnostic Substances) sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2026-01-07 00:05 | 2026-01-02 | Whitfield Dianne C. | Officer - Chief Human Resources Officer | SELL | $80.67 | 15,565 | $1,255,685 | 23,393 | -40.0% |
| 2025-12-31 00:26 | 2025-12-24 | Azamian Bobak R. | Director, Officer - President/CEO and Board Chair | SELL | $82.51 | 6,000 | $495,089 | 857,991 | -0.7% |
| 2025-12-19 00:09 | 2025-12-16 | Whitfield Dianne C. | Officer - Chief Human Resources Officer | SELL | $80.10 | 7,397 | $592,500 | 38,958 | -16.0% |
| 2025-12-18 00:07 | 2025-12-15 | LINK WILLIAM J PHD | Director | SELL | $81.26 | 22,946 | $1,864,677 | 0 | -100.0% |
| 2025-12-18 00:07 | 2025-12-16 | Lin Elizabeth Yeu | Officer - Chief Medical Officer | OPT+S | $79.50 | 2,078 | $165,201 | 21,941 | 0.0% |
| 2025-09-26 23:08 | 2025-09-24 | Azamian Bobak R. | Director, Officer - President/CEO and Board Chair | SELL | $55.37 | 6,000 | $332,220 | 812,106 | -0.7% |
| 2025-09-11 00:03 | 2025-09-08 | LINK WILLIAM J PHD | Director | SELL | $57.00 | 27,116 | $1,545,612 | 143,332 | -15.9% |
| 2025-08-13 23:32 | 2025-08-11 | Azamian Bobak R. | Director, Officer - President/CEO and Board Chair | SELL | $50.00 | 6,000 | $300,000 | 818,106 | -0.7% |
| 2025-06-18 23:07 | 2025-06-17 | Farrow Jeffrey S | Officer - See Remarks | OPT+S | $40.42 | 13,608 | $550,035 | 36,704 | 0.0% |
| 2025-06-17 23:07 | 2025-06-16 | Lin Elizabeth Yeu | Officer - Chief Medical Officer | OPT+S | $41.08 | 1,006 | $41,326 | 7,694 | 0.0% |
| 2025-06-11 23:50 | 2025-06-09 | Mottiwala Aziz | Officer - Chief Commercial Officer | SELL | $43.76 | 17,500 | $765,800 | 47,557 | -26.9% |
| 2025-03-26 23:47 | 2025-03-24 | Azamian Bobak R. | Director, Officer - President/CEO and Board Chair | SELL | $50.00 | 6,000 | $300,000 | 824,106 | -0.7% |
| 2025-03-21 04:49 | 2025-03-18 | Mottiwala Aziz | Officer - Chief Commercial Officer | SELL | $47.88 | 10,565 | $505,856 | 65,057 | -14.0% |
| 2025-03-21 04:49 | 2025-03-18 | Neervannan Seshadri | Officer - Chief Operating Officer | SELL | $47.89 | 7,583 | $363,142 | 79,682 | -8.7% |
| 2025-03-21 04:49 | 2025-03-18 | Wahl Bryan | Officer - General Counsel | SELL | $47.88 | 9,686 | $463,766 | 51,712 | -15.8% |
| 2025-03-21 04:48 | 2025-03-18 | Whitfield Dianne C. | Officer - Chief Human Resources Officer | SELL | $47.88 | 6,711 | $321,323 | 46,355 | -12.6% |
| 2025-03-21 04:48 | 2025-03-18 | Azamian Bobak R. | Director, Officer - President/CEO and Board Chair | SELL | $48.03 | 24,216 | $1,163,051 | 53,635 | -31.1% |
| 2025-03-21 04:48 | 2025-03-18 | Farrow Jeffrey S | Officer - See Remarks | SELL | $47.88 | 3,724 | $178,306 | 22,431 | -14.2% |
| 2024-08-14 23:34 | 2024-08-12 | LINK WILLIAM J PHD | Director | SELL | $26.08 | 35,000 | $912,961 | 0 | -100.0% |
| 2024-06-20 23:26 | 2024-06-18 | Farrow Jeffrey S | Officer - See Remarks | OPT+S | $27.47 | 10,445 | $286,924 | 18,136 | 0.0% |
| 2024-03-20 02:08 | 2024-03-18 | Mottiwala Aziz | Officer - Chief Commercial Officer | OPT+S | $30.60 | 4,766 | $145,840 | 54,075 | 0.0% |
| 2024-03-20 02:05 | 2024-03-18 | Wahl Bryan | Officer - General Counsel | OPT+S | $30.60 | 4,436 | $135,742 | 40,951 | 0.0% |
| 2024-03-20 02:05 | 2024-03-18 | Azamian Bobak R. | Director, Officer - President/CEO and Board Chair | OPT+S | $30.60 | 10,415 | $318,699 | 26,456 | 0.0% |
| 2024-03-20 02:04 | 2024-03-18 | Whitfield Dianne C. | Officer - Chief Human Resources Officer | OPT+S | $30.60 | 4,314 | $132,008 | 34,181 | 0.0% |
| 2024-03-20 02:03 | 2024-03-18 | Neervannan Seshadri | Officer - Chief Operating Officer | OPT+S | $30.60 | 4,879 | $149,297 | 64,767 | 0.0% |
| 2023-12-30 01:08 | 2023-12-27 | Azamian Bobak R. | Director, Officer - President/CEO and Board Chair | SELL | $20.22 | 8,000 | $161,760 | 830,106 | -1.0% |
| 2023-12-23 01:32 | 2023-12-20 | Trevejo Jose M. | Officer - CHIEF MEDICAL OFFICER | SELL | $20.00 | 2,252 | $45,040 | 2,251 | -50.0% |
| 2023-12-23 01:30 | 2023-12-20 | Azamian Bobak R. | Director, Officer - President/CEO and Board Chair | SELL | $20.27 | 40,000 | $810,624 | 838,106 | -4.6% |
| 2023-12-20 02:30 | 2023-12-15 | Goldberg Andrew D. | Director | BUY | $18.96 | 1,000 | $18,960 | 3,000 | +50.0% |
| 2023-12-02 00:58 | 2023-11-30 | Whitfield Dianne C. | Officer - Chief Human Resources Officer | OPT+S | $16.31 | 8,355 | $136,270 | 26,784 | 0.0% |
| 2023-12-02 00:55 | 2023-11-30 | Wahl Bryan | Officer - General Counsel | OPT+S | $16.31 | 8,356 | $136,286 | 31,966 | 0.0% |
| 2023-11-18 00:50 | 2023-11-15 | Azamian Bobak R. | Director, Officer - President/CEO and Board Chair | SELL | $18.37 | 8,000 | $146,933 | 878,106 | -0.9% |
| 2023-10-20 23:41 | 2023-10-18 | Azamian Bobak R. | Director, Officer - President/CEO and Board Chair | SELL | $13.24 | 8,000 | $105,920 | 886,106 | -0.9% |
| 2023-10-07 00:21 | 2023-10-05 | Trevejo Jose M. | Officer - CHIEF MEDICAL OFFICER | SELL | $18.00 | 1,604 | $28,872 | 4,503 | -26.3% |
| 2023-09-23 00:30 | 2023-09-20 | Azamian Bobak R. | Director, Officer - President/CEO and Board Chair | SELL | $17.21 | 8,000 | $137,680 | 894,106 | -0.9% |
| 2023-08-26 00:12 | 2023-08-23 | Azamian Bobak R. | Director, Officer - President/CEO and Board Chair | SELL | $17.23 | 8,000 | $137,840 | 902,106 | -0.9% |
| 2023-08-18 01:02 | 2023-08-15 | Lin Elizabeth Yeu | Director | BUY | $16.80 | 9,506 | $159,701 | 15,866 | +149.5% |
| 2023-07-22 00:46 | 2023-07-19 | Mottiwala Aziz | Officer - Chief Commercial Officer | SELL | $20.05 | 2,400 | $48,120 | 45,806 | -5.0% |
| 2023-07-22 00:42 | 2023-07-19 | Azamian Bobak R. | Director, Officer - President/CEO and Board Chair | SELL | $20.01 | 103,900 | $2,078,987 | 910,106 | -10.2% |
| 2023-07-14 23:40 | 2023-07-12 | Azamian Bobak R. | Director, Officer - President/CEO and Board Chair | SELL | $17.35 | 9,000 | $156,150 | 1,014,006 | -0.9% |
| 2023-06-23 23:29 | 2023-06-21 | Azamian Bobak R. | Director, Officer - President/CEO and Board Chair | SELL | $18.63 | 8,000 | $149,040 | 1,023,006 | -0.8% |
| 2023-06-16 23:48 | 2023-06-14 | Azamian Bobak R. | Director, Officer - President/CEO and Board Chair | SELL | $18.58 | 9,000 | $167,220 | 1,031,006 | -0.9% |
| 2023-06-13 00:40 | 2023-06-08 | Azamian Bobak R. | Director, Officer - President/CEO and Board Chair | SELL | $20.01 | 3,100 | $62,031 | 1,040,006 | -0.3% |
| 2023-06-13 00:25 | 2023-06-08 | Mottiwala Aziz | Officer - Chief Commercial Officer | SELL | $20.00 | 100 | $2,000 | 48,086 | -0.2% |
| 2023-06-09 02:16 | 2023-06-06 | Mottiwala Aziz | Officer - Chief Commercial Officer | SELL | $19.00 | 4,643 | $88,231 | 48,186 | -8.8% |
| 2023-05-20 02:08 | 2023-05-17 | Azamian Bobak R. | Director, Officer - President/CEO and Board Chair | SELL | $15.90 | 8,000 | $127,200 | 1,043,106 | -0.8% |
| 2023-05-13 00:08 | 2023-05-10 | Azamian Bobak R. | Director, Officer - President/CEO and Board Chair | SELL | $16.80 | 9,000 | $151,200 | 1,051,106 | -0.8% |
| 2023-05-03 02:06 | 2023-04-28 | Azamian Bobak R. | Director, Officer - President/CEO and Board Chair | SELL | $15.11 | 10,119 | $152,925 | 1,060,106 | -0.9% |
| 2023-04-26 00:22 | 2023-04-21 | Azamian Bobak R. | Director, Officer - President/CEO and Board Chair | SELL | $15.03 | 2,311 | $34,734 | 1,070,225 | -0.2% |
| 2023-04-22 00:53 | 2023-04-20 | Greenstein Leonard M. | Officer - Chief Financial Officer | SELL | $14.02 | 5,000 | $70,100 | 26,785 | -15.7% |
How to Interpret $TARS Trades
Not every insider transaction in Tarsus Pharmaceuticals, Inc. is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $TARS shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for TARS
Insider activity data for Tarsus Pharmaceuticals, Inc. is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $TARS, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.